158 related articles for article (PubMed ID: 825327)
1. Oral hydralazine therapy for chronic refractory heart failure.
Chatterjee K; Parmley WW; Massie B; Greenberg B; Werner J; Klausner S; Norman A
Circulation; 1976 Dec; 54(6):879-83. PubMed ID: 825327
[TBL] [Abstract][Full Text] [Related]
2. Oral hydralazine in chronic heart failure: sustained beneficial hemodynamic effects.
Chatterjee K; Ports TA; Brundage BH; Massie B; Holly AN; Parmley WW
Ann Intern Med; 1980 May; 92(5):600-4. PubMed ID: 7386999
[TBL] [Abstract][Full Text] [Related]
3. Differences in hemodynamic response to vasodilation due to calcium channel antagonism with nifedipine and direct-acting agonism with hydralazine in chronic refractory congestive heart failure.
Elkayam U; Weber L; McKay CR; Rahimtoola SH
Am J Cardiol; 1984 Jul; 54(1):126-31. PubMed ID: 6741802
[TBL] [Abstract][Full Text] [Related]
4. Results of long-term vasodilator therapy in patients with refractory congestive heart failure.
Walsh WF; Greenberg BH
Circulation; 1981 Sep; 64(3):499-505. PubMed ID: 7261282
[TBL] [Abstract][Full Text] [Related]
5. Ambulatory long-term vasodilator therapy for chronic refractory heart failure: hemodynamic evaluation and clinical response.
Saito S; Ichikawa M; Ozawa Y; Yumikura S; Nagasawa M; Hibiya K; Tamura Y; Tomobe K; Hatano M
Jpn Circ J; 1984 Apr; 48(4):350-6. PubMed ID: 6425526
[TBL] [Abstract][Full Text] [Related]
6. Variable hemodynamic response to oral hydralazine in patients with refractory congestive heart failure.
LeJemtel TH; Elkayam U; Ribner HS; Hellman C; Strom J; Frishman W; Strobeck J; Sonnenblick EH
Eur Heart J; 1980 Jun; 1(3):157-63. PubMed ID: 7026250
[No Abstract] [Full Text] [Related]
7. Long-term vasodilator therapy for heart failure: clinical response and its relationship to hemodynamic measurements.
Massie B; Ports T; Chatterjee K; Parmley W; Ostland J; O'Young J; Haughom F
Circulation; 1981 Feb; 63(2):269-78. PubMed ID: 6778625
[TBL] [Abstract][Full Text] [Related]
8. Hemodynamic responses to combined therapy with captopril and hydralazine in patients with severe heart failure.
Massie BM; Packer M; Hanlon JT; Combs DT
J Am Coll Cardiol; 1983 Aug; 2(2):338-44. PubMed ID: 6345633
[TBL] [Abstract][Full Text] [Related]
9. Acute hemodynamic effects of endralazine: a new vasodilator for chronic refractory congestive heart failure.
Quyyumi AA; Wagstaff D; Evans TR
Am J Cardiol; 1983 May; 51(8):1353-7. PubMed ID: 6846162
[TBL] [Abstract][Full Text] [Related]
10. Dynamic responses to continuous use of prazosin and hydralazine in patients with refractory heart failure.
Elkayam U; Mathur M; Frishman W; LeJemtel T; Strom J; Sonnenblick EH
Clin Pharmacol Ther; 1981 Jul; 30(1):23-30. PubMed ID: 7237894
[TBL] [Abstract][Full Text] [Related]
11. Hemodynamic advantage of combined administration of hydralazine orally and nitrates nonparenterally in the vasodilator therapy of chronic heart failure.
Massie B; Chatterjee K; Werner J; Greenberg B; Hart R; Parmley WW
Am J Cardiol; 1977 Nov; 40(5):794-801. PubMed ID: 411364
[TBL] [Abstract][Full Text] [Related]
12. Hemodynamic effects of hydralazine in infants with a large ventricular septal defect.
Beekman RH; Rocchini AP; Rosenthal A
Circulation; 1982 Mar; 65(3):523-8. PubMed ID: 6459891
[TBL] [Abstract][Full Text] [Related]
13. Central hemodynamic effects of dipyridamole in severe heart failure: comparison with hydralazine.
Packer M; Gorlin R; Meller J; Medina N
Clin Pharmacol Ther; 1982 Jul; 32(1):54-61. PubMed ID: 7083730
[TBL] [Abstract][Full Text] [Related]
14. Prevention of tolerance to hemodynamic effects of nitrates with concomitant use of hydralazine in patients with chronic heart failure.
Gogia H; Mehra A; Parikh S; Raman M; Ajit-Uppal J; Johnson JV; Elkayam U
J Am Coll Cardiol; 1995 Dec; 26(7):1575-80. PubMed ID: 7594088
[TBL] [Abstract][Full Text] [Related]
15. Hemodynamic characterization of tolerance to long-term hydralazine therapy in severe chronic heart failure.
Packer M; Meller J; Medina N; Yushak M; Gorlin R
N Engl J Med; 1982 Jan; 306(2):57-62. PubMed ID: 7053487
[TBL] [Abstract][Full Text] [Related]
16. The effects of oral hydralazine on right ventricular end-diastolic pressure in patients with right ventricular failure.
Rubin LJ; Handel F; Peter RH
Circulation; 1982 Jun; 65(7):1369-73. PubMed ID: 7074795
[TBL] [Abstract][Full Text] [Related]
17. Hemodynamic effects of hydralazine in infants with idiopathic dilated cardiomyopathy and congestive heart failure.
Artman M; Parrish MD; Appleton S; Boucek RJ; Graham TP
Am Heart J; 1987 Jan; 113(1):144-50. PubMed ID: 3799428
[TBL] [Abstract][Full Text] [Related]
18. Acute hemodynamic effects of hydralazine in dogs with chronic mitral regurgitation.
Kittleson MD; Johnson LE; Oliver NB
J Am Vet Med Assoc; 1985 Aug; 187(3):258-61. PubMed ID: 4030462
[TBL] [Abstract][Full Text] [Related]
19. Acute and long-term effects of vasodilator therapy on resting and exercise hemodynamics and exercise tolerance.
Massie BM; Kramer B; Haughom F
Circulation; 1981 Dec; 64(6):1218-26. PubMed ID: 6794935
[TBL] [Abstract][Full Text] [Related]
20. Hemodynamic comparison of primary venous or arteriolar dilatation and the subsequent effect of furosemide in left ventricular failure after acute myocardial infarction.
Nelson GI; Silke B; Forsyth DR; Verma SP; Hussain M; Taylor SH
Am J Cardiol; 1983 Nov; 52(8):1036-40. PubMed ID: 6637819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
